Loading
A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC is a phase 2 interventional study registered as NCT07586202 by Janssen Research & Development, LLC, with 68 participants planned, started 2026-07-28 and due to reach its primary completion in 2028-03-02. Interventions recorded: Amivantamab, Lazertinib, Carboplatin and Pemetrexed.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/